After adjusting for age, febuxostat dosage, ALT, and hyperlipidemia, underlying liver disease was independently associated with a 4.1-fold increase in the risk of developing hepatotoxicity (OR, 4.083; 95% CI, 1.326–12.577; p = 0.014) (Table 3). Here, GPT is linked to hyperlipidemia.